Results 311 to 320 of about 900,371 (377)

Influence of sleep architectural disruptions on evolution of atrial fibrillation. [PDF]

J Clin Sleep Med
Heinzinger CM, Mehra R.
europepmc   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Francisca Saraiva, Ana C. Oliveira, Jorge Almeida, Ana Beatriz Batista, Arsénio Barbosa, Ana Filipa Ferreira, Cátia Costa, Diogo Santos‐Ferreira, Fernando Friões, Cândida Goncalves, João Tiago Guimarães, Marta Leite, Pedro Marques, Joana Mascarenhas, Maria Inês Matos, Catarina Pereira, Pedro Rodrigues, Abhinav Sharma, Gualter Silva, Inês Pereira‐Sousa, Carla Sousa, Faiez Zannad, Joana Pimenta, Ricardo Fontes‐Carvalho, Adelino Leite‐Moreira   +26 more
wiley   +1 more source

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair

ESC Heart Failure, EarlyView.
Abstract Aims Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge‐to‐edge mitral valve repair (M‐TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.
Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bouta, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Daisuke Hachinohe, Toshiaki Otsuka, Shunsuke Kubo, Kentaro Hayashida, OCEAN‐Mitral Investigators   +30 more
wiley   +1 more source

Atrial fibrillation does not equal atrial fibrillation: The important prognostic implications of new-onset atrial fibrillation. [PDF]

Int J Cardiol Heart Vasc
Goette A, De Caterina R, de Groot JR, Dobrev D.   +3 more
europepmc   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

ESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang, Rui Fan, Shaozhao Zhang, Junlin Zhong, Yiquan Huang, Peihan Xie, Shanshan Yin, Xiaomin Ye, Xinghao Xu, Rihua Huang, Zhenyu Xiong, Yue Guo, Menghui Liu, Yifen Lin, Suhua Li, Xiaoxian Qian, Jinlai Liu, Xiaodong Zhuang, Xinxue Liao   +18 more
wiley   +1 more source

Optimal timing for atrial fibrillation patients to undergo catheter ablation. [PDF]

Commun Med (Lond)
Lin M, Liang H, Zhang K, Chen T, Wang J, Han W, Rong B, Zhong J.   +7 more
europepmc   +1 more source

Clinical characteristics and long‐term outcomes in patients with apical hypertrophic cardiomyopathy

ESC Heart Failure, EarlyView.
Abstract Aims As a special type of hypertrophic cardiomyopathy (HCM), apical HCM (ApHCM) has different clinical characteristics while its nature history and prognosis are not well recognized. We aimed to describe the characteristics and outcomes of ApHCM and identify predictors of adverse outcomes.
Meng Guo, Chuanfen Liu, Jingjing Ye, Jian Liu   +3 more
wiley   +1 more source